MX2023004796A - Compuestos, composiciones y metodos de uso para tratar fracturas oseas. - Google Patents
Compuestos, composiciones y metodos de uso para tratar fracturas oseas.Info
- Publication number
- MX2023004796A MX2023004796A MX2023004796A MX2023004796A MX2023004796A MX 2023004796 A MX2023004796 A MX 2023004796A MX 2023004796 A MX2023004796 A MX 2023004796A MX 2023004796 A MX2023004796 A MX 2023004796A MX 2023004796 A MX2023004796 A MX 2023004796A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compounds
- compositions
- bone fractures
- treat bone
- Prior art date
Links
- 208000010392 Bone Fractures Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940124325 anabolic agent Drugs 0.000 abstract 1
- 239000003263 anabolic agent Substances 0.000 abstract 1
- 230000003642 osteotropic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105669P | 2020-10-26 | 2020-10-26 | |
| US202163193748P | 2021-05-27 | 2021-05-27 | |
| PCT/US2021/047824 WO2022093373A1 (en) | 2020-10-26 | 2021-08-26 | Compounds,compositions and methods of use to treat bone fractures |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004796A true MX2023004796A (es) | 2023-07-18 |
Family
ID=81383093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004796A MX2023004796A (es) | 2020-10-26 | 2021-08-26 | Compuestos, composiciones y metodos de uso para tratar fracturas oseas. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230399374A1 (https=) |
| EP (1) | EP4232074A4 (https=) |
| JP (1) | JP2024506435A (https=) |
| AU (1) | AU2021370296A1 (https=) |
| CA (1) | CA3194776A1 (https=) |
| MX (1) | MX2023004796A (https=) |
| WO (1) | WO2022093373A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018102616A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| WO2019232285A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| WO2022093374A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat spinal fusions |
| AU2022205801A1 (en) * | 2021-01-05 | 2023-07-13 | Radius Health, Inc. | Treatment of long bone fractures with abaloparatide |
| CN117373681B (zh) * | 2023-10-30 | 2024-04-26 | 中国航天科工集团七三一医院 | 一种基于血糖调节系统作用的骨折愈合仿真方法及系统 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2883707A1 (en) * | 2012-08-28 | 2014-03-06 | The Governors Of The University Of Alberta | Parathyroid hormone, insulin, and related peptides conjugated to bone targeting moieties and methods of making and using thereof |
| WO2018102616A1 (en) * | 2016-11-30 | 2018-06-07 | Purdue Research Foundation | Fracture targeted bone regeneration through parathyroid hormone receptor stimulation |
| WO2019232285A1 (en) * | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| WO2022093374A1 (en) * | 2020-10-26 | 2022-05-05 | Purdue Research Foundation | Compounds,compositions and methods of use to treat spinal fusions |
-
2021
- 2021-08-26 WO PCT/US2021/047824 patent/WO2022093373A1/en not_active Ceased
- 2021-08-26 MX MX2023004796A patent/MX2023004796A/es unknown
- 2021-08-26 JP JP2023525002A patent/JP2024506435A/ja active Pending
- 2021-08-26 AU AU2021370296A patent/AU2021370296A1/en active Pending
- 2021-08-26 EP EP21887113.5A patent/EP4232074A4/en active Pending
- 2021-08-26 CA CA3194776A patent/CA3194776A1/en active Pending
- 2021-08-26 US US18/033,665 patent/US20230399374A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4232074A4 (en) | 2025-03-05 |
| AU2021370296A1 (en) | 2023-06-22 |
| WO2022093373A1 (en) | 2022-05-05 |
| CA3194776A1 (en) | 2022-05-05 |
| JP2024506435A (ja) | 2024-02-14 |
| AU2021370296A9 (en) | 2024-09-12 |
| EP4232074A1 (en) | 2023-08-30 |
| US20230399374A1 (en) | 2023-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004796A (es) | Compuestos, composiciones y metodos de uso para tratar fracturas oseas. | |
| PH12020550901A1 (en) | Macrocyclic compounds for treating disease | |
| PH12022551513A1 (en) | Sos1 inhibitors | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| MX2024006824A (es) | Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos. | |
| PH12022550286A1 (en) | Deuterated compounds for use in the treatment of cancer | |
| ZA201802496B (en) | Jak kinase inhibitor compounds for treatment of respiratory disease | |
| MY183036A (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| MY182590A (en) | Benzylamine derivatives | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| ZA202003554B (en) | 1 -(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| PH12018502056B1 (en) | Methods of treatment of cholestatic diseases | |
| MX2024013215A (es) | Compuestos para inhibir kif18a | |
| MX382162B (es) | Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer. | |
| PH12021553132A1 (en) | Methods of using rad51 inhibitors for treatment of pancreatic cancer | |
| PH12018502337A1 (en) | Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions | |
| ZA202403747B (en) | Compounds and their uses as gpr183 inhibitors | |
| MX2024006684A (es) | Inhibidores de hdac novedosos y uso terapéutico de estos. | |
| WO2023097194A3 (en) | Bicyclic therapeutic compounds and methods of use in the treatment of cancer | |
| WO2022093374A8 (en) | Compounds,compositions and methods of use to treat spinal fusions | |
| PH12022552489A1 (en) | V delta1+ t cells for the treatment of myeloid malignancies | |
| AU2021369193A9 (en) | Compounds,compositions and methods of use to treat spinal fusions | |
| PH12021552133A1 (en) | Aromatic derivatives, preparation methods, and medical uses thereof | |
| EA201591793A1 (ru) | Лактамные соединения в качестве селективных агонистов ep4-рецепторов для применения при лечении опосредованных ep4 заболеваний и состояний |